ID   LIM2405
AC   CVCL_4437
SY   LIM 2405; LIM-2405
DR   BioSample; SAMN07624416
DR   cancercelllines; CVCL_4437
DR   CBA; CBA-0165
DR   ColonAtlas; LIM2405
DR   Cosmic; 1238054
DR   Cosmic; 1482518
DR   Cosmic; 1486137
DR   Cosmic; 1524339
DR   Cosmic; 1676726
DR   Cosmic; 1805261
DR   Cosmic; 2301994
DR   ECACC; 12062003
DR   GEO; GSM1346880
DR   GEO; GSM1448126
DR   GEO; GSM3145717
DR   PRIDE; PXD000120
DR   Wikidata; Q54902532
RX   PubMed=1427983;
RX   PubMed=19378335;
RX   PubMed=23458625;
RX   PubMed=24295106;
RX   PubMed=24755471;
RX   PubMed=25926053;
RX   PubMed=25944804;
CC   From: Ludwig Institute for Cancer Research, Melbourne Branch; Melbourne; Australia.
CC   Doubling time: 24 hours (PubMed=1427983); 30.72 hours (PubMed=25944804).
CC   Microsatellite instability: Instable (MSI) (PubMed=19378335; PubMed=24755471; PubMed=25926053).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Ala697Val (c.2090C>T); ClinVar=VCV000216153; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Val2194Phefs*5 (c.6579delA); ClinVar=VCV001446272; Zygosity=Unspecified (PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 1097; BRAF; Simple; p.Val600Glu (c.1799T>A); ClinVar=VCV000013961; Zygosity=Unspecified (PubMed=19378335; PubMed=24755471).
CC   Sequence variation: Mutation; HGNC; 9588; PTEN; Simple; p.Val290fs*8 (c.867_868insA); Zygosity=Unspecified (PubMed=24755471).
CC   Omics: Deep proteome analysis.
CC   Omics: N-glycan profiling.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): CBA=CBA-0165; PubMed=25926053
ST   Amelogenin: X,Y
ST   CSF1PO: 14,15
ST   D13S317: 8,11
ST   D16S539: 14,15
ST   D18S51: 12,18
ST   D19S433: 13,14.2,15.2
ST   D21S11: 29,30 (PubMed=25926053)
ST   D21S11: 29,31 (CBA=CBA-0165)
ST   D2S1338: 17,19
ST   D3S1358: 15,16
ST   D5S818: 12,13
ST   D7S820: 7,8
ST   D8S1179: 10,12
ST   FGA: 19,21
ST   TH01: 9.3
ST   TPOX: 8
ST   vWA: 14,18 (PubMed=25926053)
ST   vWA: 14,18,19 (CBA=CBA-0165)
DI   NCIt; C5543; Cecum adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Male
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 02-05-24; Version: 29
//
RX   PubMed=1427983; DOI=10.1038/icb.1992.30;
RA   Whitehead R.H., Zhang H.H., Hayward I.P.;
RT   "Retention of tissue-specific phenotype in a panel of colon carcinoma
RT   cell lines: relationship to clinical correlates.";
RL   Immunol. Cell Biol. 70:227-236(1992).
//
RX   PubMed=19378335; DOI=10.1002/ijc.24289;
RA   Zhang H.-H., Walker F., Kiflemariam S., Whitehead R.H., Williams D.,
RA   Phillips W.A., Mikeska T., Dobrovic A., Burgess A.W.;
RT   "Selective inhibition of proliferation in colorectal carcinoma cell
RT   lines expressing mutant APC or activated B-Raf.";
RL   Int. J. Cancer 125:297-307(2009).
//
RX   PubMed=23458625; DOI=10.1021/pr3010869;
RA   Fanayan S., Smith J.T., Lee L.Y., Yan F.-F., Snyder M.P., Hancock W.S.,
RA   Nice E.;
RT   "Proteogenomic analysis of human colon carcinoma cell lines LIM1215,
RT   LIM1899, and LIM2405.";
RL   J. Proteome Res. 12:1732-1742(2013).
//
RX   PubMed=24295106; DOI=10.1021/pr400861m;
RA   Sethi M.K., Thaysen-Andersen M., Smith J.T., Baker M.S., Packer N.H.,
RA   Hancock W.S., Fanayan S.;
RT   "Comparative N-glycan profiling of colorectal cancer cell lines
RT   reveals unique bisecting GlcNAc and alpha-2,3-linked sialic acid
RT   determinants are associated with membrane proteins of the more
RT   metastatic/aggressive cell lines.";
RL   J. Proteome Res. 13:277-288(2014).
//
RX   PubMed=24755471; DOI=10.1158/0008-5472.CAN-14-0013;
RA   Mouradov D., Sloggett C., Jorissen R.N., Love C.G., Li S.,
RA   Burgess A.W., Arango D., Strausberg R.L., Buchanan D., Wormald S.,
RA   O'Connor L., Wilding J.L., Bicknell D.C., Tomlinson I.P.M., Bodmer W.F.,
RA   Mariadason J.M., Sieber O.M.;
RT   "Colorectal cancer cell lines are representative models of the main
RT   molecular subtypes of primary cancer.";
RL   Cancer Res. 74:3238-3247(2014).
//
RX   PubMed=25926053; DOI=10.1038/ncomms8002;
RA   Medico E., Russo M., Picco G., Cancelliere C., Valtorta E., Corti G.,
RA   Buscarino M., Isella C., Lamba S., Martinoglio B., Veronese S.,
RA   Siena S., Sartore-Bianchi A., Beccuti M., Mottolese M.,
RA   Linnebacher M., Cordero F., Di Nicolantonio F., Bardelli A.;
RT   "The molecular landscape of colorectal cancer cell lines unveils
RT   clinically actionable kinase targets.";
RL   Nat. Commun. 6:7002.1-7002.10(2015).
//
RX   PubMed=25944804; DOI=10.1158/1078-0432.CCR-14-2457;
RA   Bazzocco S., Dopeso H., Carton-Garcia F., Macaya I., Andretta E.,
RA   Chionh F., Rodrigues P., Garrido M., Alazzouzi H., Nieto R.,
RA   Sanchez A., Schwartz S. Jr., Bilic J., Mariadason J.M., Arango D.;
RT   "Highly expressed genes in rapidly proliferating tumor cells as new
RT   targets for colorectal cancer treatment.";
RL   Clin. Cancer Res. 21:3695-3704(2015).
//